Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematisk översikt with metaanalys on randomized controlled trials

Zhang, Poon och Wong gick igenom 4 049 poster och inkluderade 12 randomiserade kontrollerade studier med totalt 513 deltagare. Random-effects metaanalys found a significant overall effect of NMN on elevating blood NAD levels. Fasting glucose did not change significantly (mean difference -0.39 mg/dL, 95% CI -2.52 to 1.75, p=0.683). Physical performance showed a non-significant trend toward improvement (standardized mean difference 0.24, 95% CI -0.03 to 0.50, p=0.074). Triglycerides did decrease significantly in participants who were overweight or obese. Risk-of-bias assessment using RoB2 found some concerns in seven of the 12 trials and high risk of bias in the other five. Side effects were mostly mild gastrointestinal issues (diarrhea, abdominal pain), with no significant change in liver enzymes at doses up to 1250 mg/day. The authors' bottom line: NMN reliably boosts blood NAD and gives a moderate triglyceride improvement in overweight or obese people, but most clinically relevant outcomes and body composition changes are not proven effective in humans. This is one of the two major NMN meta-analyses to read alongside the Chen/Zhou 2024 Current Diabetes Reports review; they draw very similar conclusions from overlapping trial pools.

In conclusion, results of this metaanalys reveal that NMN supplementation effectively boosts blood NAD levels and provides a moderate improvement in TG levels in overweight/obese participants. Nonetheless, most of the clinically relevant outcomes and body composition were not proven effective in humans receiving NMN supplementation.